LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Akciju saraksts・Innoviva Inc

Innoviva Inc

Slēgts

SektorsVeselības aprūpe

22.54 0.94

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

22.03

Max

22.68

Galvenie mērījumi
By Trading Economics
Ienākumi	-55M 187M
Pārdošana	-20M 98M
P/E Sektora vidējais	3.436 49.888
EPS	0.47
Peļņas marža	190.415
Darbinieki	159
EBITDA	-160M 48M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+54.5% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-115M 1.6B
Iepriekšējā atvēršanas cena	21.6
Iepriekšējā slēgšanas cena	22.54

Ziņu noskaņojums

By Acuity

47%

53%

151 / 344 Rangs Healthcare

Innoviva Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. jūn. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

2026. g. 8. jūn. 15:41 UTC

Galvenie tirgus virzītāji

American Battery Shares Jump on Energy Department Victory

2026. g. 8. jūn. 23:46 UTC

Tirgus saruna

Nikkei May Rebound After Monday's Selloff -- Market Talk

2026. g. 8. jūn. 23:37 UTC

Tirgus saruna

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

2026. g. 8. jūn. 23:25 UTC

Tirgus saruna

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

2026. g. 8. jūn. 23:25 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 8. jūn. 21:57 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

2026. g. 8. jūn. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce Agrees to Buy m3ter

2026. g. 8. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 8. jūn. 19:22 UTC

Tirgus saruna

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

2026. g. 8. jūn. 19:01 UTC

Tirgus saruna

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

2026. g. 8. jūn. 18:52 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 8. jūn. 18:52 UTC

Tirgus saruna

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

2026. g. 8. jūn. 18:17 UTC

Tirgus saruna

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

2026. g. 8. jūn. 17:32 UTC

Tirgus saruna

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

2026. g. 8. jūn. 17:29 UTC

Tirgus saruna

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

2026. g. 8. jūn. 17:29 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 8. jūn. 16:55 UTC

Iegādes, apvienošanās, pārņemšana

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

2026. g. 8. jūn. 16:54 UTC

Iegādes, apvienošanās, pārņemšana

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

2026. g. 8. jūn. 16:40 UTC

Tirgus saruna

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

2026. g. 8. jūn. 16:31 UTC

Tirgus saruna

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

2026. g. 8. jūn. 16:27 UTC

Tirgus saruna

Mexican Inflation Seen Easing in May -- Market Talk

2026. g. 8. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 8. jūn. 16:03 UTC

Iegādes, apvienošanās, pārņemšana

Orange Bought Stake From Lorca

2026. g. 8. jūn. 16:01 UTC

Iegādes, apvienošanās, pārņemšana

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

2026. g. 8. jūn. 16:01 UTC

Iegādes, apvienošanās, pārņemšana

Orange Acquires 100% Ownership of MasOrange

2026. g. 8. jūn. 15:58 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 8. jūn. 15:58 UTC

Tirgus saruna

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

2026. g. 8. jūn. 15:55 UTC

Tirgus saruna

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

2026. g. 8. jūn. 15:41 UTC

Tirgus saruna

Gold Falls Below 200-Day Moving Average -- Market Talk

Salīdzinājums

Cenas izmaiņa

Innoviva Inc Prognoze

Cenas mērķis

By TipRanks

54.5% augšup

Prognoze 12 mēnešiem

Vidējais 34.5 USD 54.5%

Augstākais 46 USD

Zemākais 18 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Innoviva Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Innoviva Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

151 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.